A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
A series of blood tests, procedures, and imaging tests can help diagnose acute myeloid leukemia (AML). Additionally, these tests can also determine its subtype and help identify the best treatment ...
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
Yatiri Bio, a precision medicine company utilizing an AI-driven proteomic platform (ProteoCharts™) to identify therapeutically sensitive patient populations, reports results from a blinded ...
Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). This is an ASCO Meeting ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results